Have a personal or library account? Click to login
The predictive value of lncRNA LAMTOR5-AS1 in the recurrence after endoscopic submucosal dissection for early gastric cancer Cover

The predictive value of lncRNA LAMTOR5-AS1 in the recurrence after endoscopic submucosal dissection for early gastric cancer

Postępy Higieny i Medycyny Doświadczalnej
Volume 78 (2024): Issue 1 (January 2024)
By: Min Chen,  Ye Zhou,  Maoling Luo,  Mingchuan Luo,  Yali Wang and  Li Jiang  
Open Access
|Sep 2024

Figures & Tables

Figure 1.

Expression and predictive ability of LAMTOR5-AS1. (a) LAMTOR5-AS1 was markedly upregulated in gastric cancer. (b) LAMTOR5-AS1 expression helps to distinguish gastric cancer patients from control individuals (AUC = 0.9076). (c) LAMTOR5-AS1 level was enhanced in the recurrent group. (d) Predictive potential of LAMTOR5-AS1 expression in early gastric cancer patients for recurrence after ESD (AUC = 0.8147). ***P < 0.001
Expression and predictive ability of LAMTOR5-AS1. (a) LAMTOR5-AS1 was markedly upregulated in gastric cancer. (b) LAMTOR5-AS1 expression helps to distinguish gastric cancer patients from control individuals (AUC = 0.9076). (c) LAMTOR5-AS1 level was enhanced in the recurrent group. (d) Predictive potential of LAMTOR5-AS1 expression in early gastric cancer patients for recurrence after ESD (AUC = 0.8147). ***P < 0.001

Figure 2.

The targeting relationship between LAMTOR5-AS1 and miR-331-3p. (a) LAMTOR5-AS1 directly targets miR-331-3p in gastric cancer. (b) miR-331-3p was decreased in gastric cancer tissue. (c) miR-331-3p expression was downregulated in the recurrence group. (d) Regulatory relationship between LAMTOR5-AS1 and miR-331-3p (r=−0.5818, P < 0.0001). (e) Transfection efficiency of silencing LAMTOR5-AS1 in cells. (f) Expression of miR-331-3p in cells after transfection with silencing LAMTOR5-AS1 and miR-331-3p inhibitor. **P < 0.01, ***P < 0.001, vs CK; #P < 0.05, vs si-LAMTOR5-AS1
The targeting relationship between LAMTOR5-AS1 and miR-331-3p. (a) LAMTOR5-AS1 directly targets miR-331-3p in gastric cancer. (b) miR-331-3p was decreased in gastric cancer tissue. (c) miR-331-3p expression was downregulated in the recurrence group. (d) Regulatory relationship between LAMTOR5-AS1 and miR-331-3p (r=−0.5818, P < 0.0001). (e) Transfection efficiency of silencing LAMTOR5-AS1 in cells. (f) Expression of miR-331-3p in cells after transfection with silencing LAMTOR5-AS1 and miR-331-3p inhibitor. **P < 0.01, ***P < 0.001, vs CK; #P < 0.05, vs si-LAMTOR5-AS1

Figure 3.

Effect of LAMTOR5-AS1 sponge miR-331-3p on gastric cancer cell proliferation (a), migration (b), and invasion (c). si-LAMTOR5-AS1 suppressed cell activity, which was reversed by miR-331-3p inhibitor. ***P < 0.001, vs CK; #P < 0.05, ##P < 0.01, vs si-LAMTOR5-AS1
Effect of LAMTOR5-AS1 sponge miR-331-3p on gastric cancer cell proliferation (a), migration (b), and invasion (c). si-LAMTOR5-AS1 suppressed cell activity, which was reversed by miR-331-3p inhibitor. ***P < 0.001, vs CK; #P < 0.05, ##P < 0.01, vs si-LAMTOR5-AS1

Relationship between LAMTOR5-AS1 and clinical indicators in patients with gastric cancer

Case (n/%)Low LAMTOR5-AS1 (n = 63)High LAMTOR5-AS1 (n = 67)P
Age (years) 0.852
≤ 5556/43.0828/44.4428/41.79
> 5574/56.9235/55.5639/58.21
Sex 0.660
Male85/65.3840/63.4945/67.16
Female45/34.6223/36.5122/32.84
Tumor size (cm) 0.054
≤ 565/50.0026/41.2739/58.21
> 565/50.0037/58.7328/41.79
Differentiation 0.227
Well, moderate61/46.9233/52.3828/41.79
Poor69/53.0830/47.6239/58.21
Recurrence 0.025
No113/86.9259/93.6554/80.60
Yes17/13.084/6.3513/19.40
TNM stage <0.001
T1a50/38.4638/60.3212/17.91
T1b80/61.5425/39.6855/82.09
Lymph node metastasis 0.008
Negative65/50.0039/61.9026/38.81
Positive65/50.0024/38.1041/61.19

Comparison of the general data of the two groups of patients

IndicatorsCase (n/%)Recurrence group (n = 17)Recurrence-free group (n = 113)P
Age (years) 0.772
≤ 5556/43.088/47.0648/42.48
> 5574/56.929/52.9465/57.52
Sex 0.542
Male85/65.3810/58.8275/66.37
Female45/34.627/41.1838/33.63
Tumor size (cm) 0.069
≤ 565/50.005/29.4160/53.10
> 565/50.0012/70.5953/46.90
Differentiation 0.009
Well, moderate61/46.923/17.6558/51.33
Poor69/53.0814/82.3555/48.67
TNM stage 0.015
T1a50/38.462/11.7648/42.48
T1b80/61.5415/88.2465/57.52
Lymph node metastasis 0.019
Negative65/50.004/23.5361/53.98
Positive65/50.0013/76.4752/46.02

Binary logistic regression analysis of recurrence of early gastric cancer after endoscopic submucosal dissection

IndicatorsOR95% CIP-value
LAMTOR5-AS10.0880.015 - 0.5160.007
Age (years)0.5490.155 - 1.9480.353
Sex (male/female)1.0850.297 - 3.9690.902
Tumor size (cm)0.1690.042 - 0.6770.012
Differentiation0.1730.040 - 0.7390.018
TNM stage0.1380.024 - 0.7890.026
Lymph node metastasis2.4110.589 - 9.8620.221
DOI: https://doi.org/10.2478/ahem-2024-0009 | Journal eISSN: 1732-2693
Journal RSS Feed
Language: English
Page range: 96 - 102
Submitted on: Apr 29, 2024
Accepted on: Jul 2, 2024
Published on: Sep 14, 2024
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
gastric cancer,
endoscopic submucosal dissection,
LAMTOR5-AS1,
recurrence,
miR-331-3p
Related subjects:
Life sciences,
Molecular biology,
Microbiology and virology,
Medicine,
Basic medical science,
Immunology

© 2024 Min Chen, Ye Zhou, Maoling Luo, Mingchuan Luo, Yali Wang, Li Jiang, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 78 (2024): Issue 1 (January 2024)Next article